Source - EurekAlert – Biology
Public Release: 30-Jun-2009
University of Leicester researchers discover new fluorescent silicon nanoparticles
Researchers in the Department of Physics and Astronomy at the University of Leicester have developed a new synthesis method, which has led them to the discovery of fluorescent silicon nanoparticles and may ultimately help track the uptake of drugs by the body's cells.
Contact: Dr Klaus von Haeften
kvh6@le.ac.uk
01-162-523-525
University of Leicester
Public Release: 30-Jun-2009
Harvard scientists solve mystery about why HIV patients are more susceptible to TB infection
Harvard scientists took an important first-step toward the development of new treatments to help people with HIV battle Mycobacterium tuberculosis infection. In a report appearing in the July 2009 print issue of the Journal of Leukocyte Biology they describe how HIV interferes with the cellular and molecular mechanisms used by the lungs to fight TB infection. This information is crucial for researchers developing new treatments.
Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Public Release: 30-Jun-2009
New test can detect both genetic and chromosomal abnormalities in embryos
One-step screening for both genetic and chromosomal abnormalities has come a stage closer as scientists announced that an embryo test they have been developing has successfully screened cells taken from spare embryos that were known to have cystic fibrosis
Contact: Mary Rice
mary@mrcommunication.org
European Society for Human Reproduction and Embryology
Public Release: 30-Jun-2009
Neural stem cell differentiation factor discovered
Neural stem cells represent the cellular backup of our brain. These cells are capable of self-renewal to form new stem cells or differentiate into neurons, astrocytes or oligodendrocytes. The receptors of the Notch family play a significant role in this process. So far, only stimulating extracellular ligands of Notch receptors had been described. Biochemists of Goethe University Medical School now describe a long time assumed but not yet identified soluble Notch inhibitor.
Contact: Mirko Schmidt
mirko.schmidt@kgu.de
49-069-630-184-157
Goethe University Frankfurt
Public Release: 29-Jun-2009
MIT: Extending the shelf life of antibody drugs
A new computer model developed at MIT can help solve a problem that has plagued drug companies trying to develop promising new treatments made of antibodies: Such drugs have a relatively short shelf life because they tend to clump together, rendering them ineffective.
Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Public Release: 29-Jun-2009
Stanford researchers publish comprehensive model for medical device development
In an effort to increase understanding of the medical device development process and help companies execute the bench-to-bedside process of product development more effectively, researchers at Stanford University have published the first comprehensive model representing the medical device development process.
Contact: Robyn Stein
Robyn.Stein@gabbe.com
212-220-4444
InHealth: The Institute for Health Technology Studies
Public Release: 29-Jun-2009
New biomarker method could increase the number of diagnostic tests for cancer
A team of researchers, including several from UCSF, has demonstrated that a new method for detecting and quantifying protein biomarkers in body fluids may ultimately make it possible to screen multiple biomarkers in hundreds of patient samples, thus ensuring that only the strongest biomarker candidates will advance down the development pipeline.
Contact: Elizabeth Fernandez
efernandez@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Public Release: 29-Jun-2009
Gene map aims to combat blood flukes
The first microsatellite-based genetic linkage map has been published for Schistosoma mansoni, a blood fluke that is known to infect over 90 million people in Africa, the Middle East and the New World. Researchers writing in BioMed Central's open-access journal Genome Biology hope the map will stimulate research and open doors to new advances in combating this neglected human pathogen.
Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-203-192-2165
BioMed Central
Source - Science Daily:
Please note: Due to the format restrictions of Science Daily articles, you must click on the URL (web address) below the article summary, rather than the article title.
Mouse Model Of Parkinson's Reproduces Nonmotor Symptoms
June 30, 2009 — Nonmotor symptoms of Parkinson's include digestive and sleep problems, loss of sense of smell and depression. A mouse with a mutation in a gene responsible for packaging neurotransmitters like ..
http://www.sciencedaily.com/releases/2009/06/090623091123.htm
Four Out Of 106 Heart Replacement Valves From Pig Hearts Failed, Study Finds
June 30, 2009 — Pig heart valves used to replace defective aortic valves in human patients failed much earlier and more often than expected, says a new report from cardiac surgeons. This is the first report to ...
http://www.sciencedaily.com/releases/2009/06/090629165554.htm
Key Culprits In Lupus Discovered
June 30, 2009 — The more than 1.5 million Americans with systemic lupus erythematosus (or lupus) suffer from a variety of symptoms that flare and subside, often including painful or swollen joints, extreme fatigue, ...
http://www.sciencedaily.com/releases/2009/06/090629200811.htm
How Much Is Life Worth? The $440 Billion Question
June 30, 2009 — The decision to use expensive cancer therapies that typically produce only a relatively short extension of survival is a serious ethical dilemma in the United States that needs to be addressed by the ...
http://www.sciencedaily.com/releases/2009/06/090629165552.htm
DNA Mutation That Occurs At Beginning Point Of T-cell Lymphoma Identified
June 30, 2009 — Researchers have identified a key mechanism that causes chromosomes within blood cells to break -- an occurrence that marks the first step in the development of human ...
http://www.sciencedaily.com/releases/2009/06/090612092743.htm
Hunt For The Blood Test To Determine Melanoma Survival Rates
June 30, 2009 — New research will be breaking new ground in the search for a simple blood test that could tell whether a patient with melanoma has the condition in an aggressive form. Melanoma is the most aggressive ...
http://www.sciencedaily.com/releases/2009/06/090630075447.htm
Nanotechnology Combats Fatal Brain Infections
June 29, 2009 — Scientists have developed novel peptide nanoparticles that effectively seek out and destroy bacteria and fungal cells that could cause fatal ...
http://www.sciencedaily.com/releases/2009/06/090628171955.htm
Synthetic Biology: Gene Therapy Gets Under The Skin
June 29, 2009 — Vaseline, a known molecule from apples and a gene network encapsulated in algal gelatin are the components of a possible gene therapy which literally gets under the skin. An important part in this is ...
http://www.sciencedaily.com/releases/2009/06/090623193112.htm
Blood Flow In Alzheimer's Disease
June 29, 2009 — Scientists have discovered that endothelin converting enzyme-2 (ECE-2) may cause the decrease in cerebral blood flow seen in Alzheimer's ...
http://www.sciencedaily.com/releases/2009/06/090624211135.htm
New Biomarker Method Could Increase The Number Of Diagnostic Tests For Cancer
June 29, 2009 — A new method for detecting and quantifying protein biomarkers in body fluids may ultimately make it possible to screen multiple biomarkers in hundreds of patient samples, thus ensuring that only the ...
http://www.sciencedaily.com/releases/2009/06/090629132208.htm
Best Heart Disease And Stroke Treatments For Patients With Diabetes Found With New Tool
June 29, 2009 — Researchers have developed a computer model that medical doctors can use to determine the best time to begin using statin therapy in diabetes patients to help prevent heart disease and ...
http://www.sciencedaily.com/releases/2009/06/090629112633.htm
Source - Health Day:
Health Highlights: June 30, 2009
- E. Coli Found in Nestlé Cookie Dough: FDA
- Daily Sex Improves Sperm Quality: Study
- Too Few Young Adults Treated for Alcohol, Drug Problems: Study
- Studies Detail New Ovary Preservation, Transplant Methods
Not just the infirm should be vaccinated, experts urge
New Drug Promising Against Rheumatoid Arthritis
Golimumab might help where similar drugs failed, research finds
Clinical Trials Update: June 29, 2009
- Weight Loss
- Bipolar Disorder
- Migraine
Source - Yahoo Biotech News:
XenoPort shares rise on positive study data
Shares of XenoPort Inc. jumped Tuesday after the biotechnology company said its experimental spinal cord injury drug met key treatment goals in a midstage study.
Geron and GE Alliance Sends Stem Cell Stocks Higher
A new deal between Geron and GE Healthcare sent the former flying on Tuesday.
BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.----BioSante Pharmaceuticals, Inc. and Cell Genesys , today announced that they have entered into a definitive merger agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company.
Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response
Source - Google Health News:
H1N1 Shows No Signs of Weakening; Numbers Rising
HSToday - Germantown,MD,USA
They are especially concerned about what could happen if H1N1 combines with the highly virulent H5N1 bird flu. WHO Director-General Dr. Margaret Chan said ...
New Flu Vaccine Approved — for Dogs
New York Times - United States
... the first vaccine for it. While fears of a flu pandemic among humans have shifted from the lethal H5N1 avian flu to the relatively mild H1N1 swine flu, ...
States Should Plan for H1N1 Vaccinations as Numbers Rise More
Wall Street Journal Blogs - New York,NY,USA
They ignored science for worst-case CFR (refused to use the H5N1 CFR for pandemic planning purposes) and now are not being honest nor science-based about ...
Large-scale H1N1 vaccine production begins -Sanofi
Reuters - USA
PA) has begun large-scale production of a vaccine for the H1N1 swine flu at its facilities in the United States and France, the company said on Thursday. ...
Source - Medical News Today:
System Accurately Predicts Spread Of H1N1
A new scientific system developed by a St. Michael's Hospital physician, designed to rapidly evaluate the world's air traffic patterns, accurately predicted how the H1N1 virus would spread around the world, according to research published in the New England Journal of Medicine. St. Michael's Hospital scientist and infectious disease physician Dr. Kamran Khan and colleagues analyzed the flight itineraries of the more than 2.3 million passengers departing Mexico on commercial flights during the months of March and April to predict the spread of H1N1. The findings show the international destinations of air travelers leaving Mexico were strongly associated with confirmed importations of the H1N1 virus around the world.
http://www.medicalnewstoday.com/articles/155893.php
The 90-Year Evolution Of Swine Flu
The current H1N1 swine flu strain has genetic roots in an illness that sickened pigs at the 1918 Cedar Rapids Swine Show in Iowa, report infectious disease experts at the University of Pittsburgh Graduate School of Public Health in the New England Journal of Medicine. Their paper, published online and slated for the July 16 print issue, describes H1N1's nearly century-long and often convoluted journey, which may include the accidental resurrection of an extinct strain. "At the same time the 1918 flu pandemic was rapidly spreading among humans, pigs were hit with a respiratory illness that closely resembled symptoms seen in people," said senior author Donald S. Burke, M.D., dean, University of Pittsburgh Graduate School of Public Health. "Early experiments confirmed that this 1918 swine virus and a human strain emerged about the same time. Since then, this ancestor virus has re-assorted genetically with other influenza strains at least four times, leading to the emergence of the new 2009 strain, which has retained some similarities to the original virus."
http://www.medicalnewstoday.com/articles/155878.php
88% Of Chronic Phase Patients With Ph+ CML Who Are Intolerant Or Resistant To Glivec Are Still Alive At 2 Years When Treated With Tasigna
New data show that at 24 months, patients in the chronic phase of Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) who are intolerant or resistant to current first-line therapy (Glivec) experienced a rapid response and significant reduction in leukaemia burden when treated with 400mg Tasigna
Personalized Anti-Cancer Vaccine, BiovaxID(R), Targeting B-Cell Lymphomas Available In Europe On A Named-Patient Basis
Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID®, Biovest's personalized therapeutic anti-cancer vaccine, is available on a named-patient (compassionate-use) basis in Europe. Following compliance with local regulatory protocols, BiovaxID will be supplied by idis Limited to European healthcare professionals for the treatment of follicular non-Hodgkin's lymphoma and potentially for other B-cell blood cancers such as chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma. Physicians in non-European countries may also contact idis to inquire about the potential availability of BiovaxID, as idis manages named-patient programs in more than 100 countries. According to world-renowned hematologist and lymphoma research pioneer, Professor Volker Diehl, M.D., Ph.D., Professor of Medicine, University of Cologne, "With the availability of this truly patient-specific vaccine, I believe hematologists now have a new, safe lymphoma treatment option capable of enhancing existing chemotherapeutic and monoclonal antibody treatment options by training the patient's own immune system to selectively recognize and attack cancer cells, resulting in potentially longer lasting remissions. As follicular lymphoma so far is supposed to be a generally incurable and fatal blood cancer, it is with great hope and expectations that I welcome such a highly personalized therapeutic approach in addressing an urgent unmet need." Prof. Dr. Diehl founded the German Hodgkin Study Group and is a recipient of the Bundesverdienstkreuz (Order of Merit of the Federal Republic of Germany), awarded by the German government for his lifetime achievements in the field of lymphoma research.
http://www.medicalnewstoday.com/articles/155794.php
Stem Cell Surprise For Tissue Regeneration
Scientists working at the Carnegie Institution's Department of Embryology, with colleagues, have overturned previous research that identified critical genes for making muscle stem cells
http://www.medicalnewstoday.com/articles/155545.php
Source - MIT's Technology Review:
Medicine's New Toolbox
http://www.technologyreview.com/biomedicine/22832/?nlid=2140
Making Tumors More Sensitive to Chemotherapy
http://www.technologyreview.com/biomedicine/22941/?nlid=2136
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.